Incyte Corporation
incyte.comTotal trials
281
Active
59
Phase 3
60
Total enrollment
48,991
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 69 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Povorcitinib | — | — | — | 16 | |||
| Ruxolitinib | — | — | 43 | ||||
| Ruxolitinib cream | — | 29 | |||||
| Vehicle Cream | — | — | — | — | 16 | ||
| INCB123667 | — | — | — | 6 | |||
| Tafasitamab | — | — | — | 8 | |||
| Lenalidomide | — | — | — | — | 5 | ||
| INCA034176 | — | — | — | — | 4 | ||
| Retifanlimab | — | — | 17 | ||||
| FOLFOX | — | — | — | — | 3 | ||
| INCA33890 | — | — | — | — | 3 | ||
| Bevacizumab | — | — | — | — | 3 | ||
| Paclitaxel | — | — | — | 9 | |||
| Rituximab | — | — | — | 8 | |||
| Cyclophosphamide | — | — | — | — | 4 | ||
| INCB161734 | — | — | — | — | 3 | ||
| Corticosteroids | — | — | — | — | 3 | ||
| Investigator's choice of chemotherapy | — | — | — | — | — | 2 | |
| Cisplatin | — | — | — | 11 | |||
| Carboplatin | — | — | — | 10 | |||
| Pemetrexed | — | — | — | 6 | |||
| nab-paclitaxel | — | — | — | 6 | |||
| Prednisone | — | — | — | — | 4 | ||
| Doxorubicin | — | — | — | — | 2 | ||
| Methotrexate | — | — | — | — | 2 | ||
| Mycophenolate mofetil | — | — | — | — | — | 2 | |
| Best Available Therapy | — | — | — | — | — | 1 | |
| Vincristine | — | — | — | — | — | 1 | |
| Tafasitamab placebo | — | — | — | — | — | 1 | |
| Lenalidomide placebo | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| INCB099280 | — | — | — | — | 6 | ||
| INCB000928 | — | — | — | — | 4 | ||
| Epacadostat | — | — | — | 20 | |||
| Parsaclisib | — | — | — | 20 | |||
| Capecitabine | — | — | — | — | 5 | ||
| INCAGN02390 | — | — | — | — | 4 | ||
| INCAGN02385 | — | — | — | — | — | 3 | |
| Regorafenib | — | — | — | — | — | 2 | |
| Best available Treatment | — | — | — | — | — | 1 |
29 more active programs hidden
Next readouts
- 2023-12-15
- 2024-02-23
- 2024-07-17
- 2025-04-01
- 2026-02-24
- 2026-03-17
- 2026-03-30
- 2026-04-14
- 2026-05-08
- 2026-05-17
Top conditions
- Solid Tumors24
- Healthy Participants16
- Atopic Dermatitis15
- Lung Cancer11
- Melanoma9
- MPN (Myeloproliferative Neoplasms)9
- Ovarian Cancer9
- Lymphoma9
Frequently asked questions about Incyte Corporation
- How many clinical trials does Incyte Corporation have on ClinicalTrials.gov?
- Incyte Corporation is listed as the lead sponsor on 281 clinical trials in ClinicalTrials.gov, 59 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Incyte Corporation's trials are in Phase 3?
- 60 of Incyte Corporation's trials are in Phase 3, spread across 69 active drug programs.
- What therapeutic areas does Incyte Corporation focus on?
- Incyte Corporation's most-studied conditions on ClinicalTrials.gov are Solid Tumors, Healthy Participants, Atopic Dermatitis, Lung Cancer, Melanoma.
- When are Incyte Corporation's next clinical trial readouts?
- Incyte Corporation has 10 upcoming primary-completion readouts tracked here; the soonest is “Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer”, expected around 2023-12-15.